Videos

Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM

Thoughtful discussion centered around recently presented updates to the MASTER trial.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

When to Perform Molecular Testing in Relapsed AML

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

An Introduction to NDMM: Treatment Options and Patient Risk Stratification

Harry P. Erba, MD, PhD, discusses the need to retest for mutations including IDH1, IDH2, FLT3, NPMI, and KMT2A rearrangement for patients with relapsed or refractory acute myeloid leukemia.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

The Role of Molecular Testing in Diagnosing Acute Myeloid Leukemia

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

A panel of clinical experts provide insights about the importance of molecular and cytogenetic testing in diagnosing acute myeloid leukemia and in determining the best treatment plan.

$CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma$

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Examining the Role of the Physician Assistant in Follicular Lymphoma

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Jennifer L. Garson, PA-C

An Introduction to Treatment Strategies for Patients with NDMM

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Patient Case Introduction: A 65-year-old Female Diagnosed with Transplant-eligible NDMM

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Managing Infections and Other Toxicities Associated with Bispecifics in MM

Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

The Development of Bispecifics-Based Combination Therapies in MM

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Best Practices for Transition of Care in Patients with MM on Teclistamab

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Administering Step-up and Treatment Doses of Bispecifics in Patients With MM

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Insights from Experts at Mayo Clinic: Sequencing Therapies in MM

Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Where Do Bispecifics Fit in the Multiple Myeloma Treatment Paradigm?

Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Other Bispecifics in Development for Multiple Myeloma

Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic